ACGT

ACGT aims to present the 'next-step' in cancer research and fill-in the technological gaps of clinical trials targeting two forms of cancer: breast cancer and paediatric nephroblastoma. ACGT will develop a Biomedical GRID infrastructure supporting seamless mediation services for sharing clinical and genomic expertise. It will help to identify quicker and more efficiently the characteristics that determine what form of treatment best suits which patient.

ACGT aims to provide researchers and patients with the best means and resources to fight cancer. ACGT is working towards the rapid identification of cancer profiles and best treatments. The ACGT project will:

  • Define common standards of data storage at each level of investigation.
  • Develop new ontologies for cross-referencing terms and their biological contexts.
  • Implement a bio-medical GRID infrastructure offering seamless mediation services for sharing data and dataprocessing.

ACGT will therefore deliver a unifying infrastructure allowing cancer researchers to share their data and to benefit from the innovative informatics tools that are being developed by other researchers.

For further information, please visit:
http://www.eu-acgt.org

Project co-ordinator:
ERCIM EEIG

Partners:

  • ERCIM EEIG - Institut National de Recherche en Informatique et en Automatique - Healthgrid (FR)
  • Foundation for Research and Technology Hellas - A. Persidis & SIA O.E. - University of Crete - Institute of Communications and Computer Systems (GR)
  • University van Amsterdam - Philips Electronics Nederland B.V. (NL)
  • Association Hospitaliere de Bruxelles – Centre Hospitalier Universitaire Bordet – Custodix - Facultes Universitaires Notre-Dame de la Paix (BE)
  • Institut Suisse de Bioinformatique (CH)
  • Lunds Universitet (SE)
  • Universidad de Malaga - Universidad Politechnica de Madrid (ES)
  • Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung - Unisersitaet Hannover - Universitaet des Saarland - Universitaet Hamburg (DE)
  • Instytut Chemii Biooganicznej pan w Poznaniu (PL)
  • S.C. SIVECO ROMANIA SA (RO)
  • The Chancellor, Masters and Scholars of the University of Oxford (UK)
  • Hokkaido University (JP)
  • Istituto Europeo di Oncologia s.r.l. (IT)

Timetable: from 02/06 - to 01/10

Total cost: € 16. 747.206

EC funding: € 11. 887.000

Instrument: Integrated Project

Project Identifier: IST-2004-026996

Most Popular Now

Do Fitness Apps do More Harm than Good?

A study published in the British Journal of Health Psychology reveals the negative behavioral and psychological consequences of commercial fitness apps reported by users on social media. These impacts may...

AI Tool Beats Humans at Detecting Parasi…

Scientists at ARUP Laboratories have developed an artificial intelligence (AI) tool that detects intestinal parasites in stool samples more quickly and accurately than traditional methods, potentially transforming how labs diagnose...

Making Cancer Vaccines More Personal

In a new study, University of Arizona researchers created a model for cutaneous squamous cell carcinoma, a type of skin cancer, and identified two mutated tumor proteins, or neoantigens, that...

AI can Better Predict Future Risk for He…

A landmark study led by University' experts has shown that artificial intelligence can better predict how doctors should treat patients following a heart attack. The study, conducted by an international...

A New AI Model Improves the Prediction o…

Breast cancer is the most commonly diagnosed form of cancer in the world among women, with more than 2.3 million cases a year, and continues to be one of the...

AI System Finds Crucial Clues for Diagno…

Doctors often must make critical decisions in minutes, relying on incomplete information. While electronic health records contain vast amounts of patient data, much of it remains difficult to interpret quickly...